Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets

PHASE1UnknownINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

August 1, 2021

Conditions
Hepatitis B
Interventions
DRUG

GST-HG141 tablets

This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.

DRUG

Placebo

This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, and 500 mg. Based on the results of a single dose, select 1 to 3 doses from 100mg, 200mg, 300mg, and 400mg to conduct multiple dose studies.

Trial Locations (1)

130000

RECRUITING

The first hospital of Jilin University, Changchun

All Listed Sponsors
lead

Fujian Cosunter Pharmaceutical Co. Ltd

INDUSTRY